An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations

Trial Profile

An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2018

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 05 Apr 2018 Status changed from planning to not yet recruiting.
    • 16 Mar 2018 New trial record
    • 12 Mar 2018 According to a Kura Oncology media release, this trial will be initiated through the Spanish Lung Cancer Group in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top